RSV vaccine to reduce COPD flare-ups
Part of Lungs & breathing clinical trials.
This study tests whether getting an RSV vaccine (a shot that protects against a common respiratory virus) can reduce the number of COPD flare-ups in people who have frequent episodes. If you qualify, you may receive the vaccine and be followed for a year to see if it helps keep you out of the hospital.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years old or older.
- You have been diagnosed with COPD, confirmed by a breathing test (spirometry).
- You are a current or former smoker with at least a 10 pack-year smoking history (e.g., a pack a day for 10 years).
- You have a history of frequent flare-ups: at least 2 moderate flare-ups or 1 severe flare-up that needed hospitalization in the past year.
- You have been on a specific type of daily inhaler (a combination of two long-acting bronchodilators) for at least 8 weeks.
- You have had your flu and pneumonia vaccines at least a month ago, and you are willing to receive an RSV vaccine (if you haven't had one already).
- You do not have other major lung conditions (like asthma or bronchiectasis) that mainly explain your symptoms.
- You are not immunocompromised or on long-term high-dose steroids (like prednisone 10 mg or more per day for 2+ weeks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how older adults' immune systems respond to a mild RSV virus given as a nasal spray. It helps researchers understand RSV and may lead to better vaccines or treatments.
This study tests an experimental vaccine to see if it is safe for healthy adults. The vaccine is made with mRNA technology and aims to protect against RSV, a common respiratory virus.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.